On May 16, 2019 BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, reported data presentations on its investigational anti-PD-1 antibody tislelizumab and its investigational BTK inhibitor zanubrutinib from four posters at the 24th Congress of the European Hematology Association (EHA) (Free EHA Whitepaper), taking place June 13-16, 2019 in Amsterdam (Press release, BeiGene, MAY 16, 2019, View Source [SID1234536440]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Presentations:

Title: Tislelizumab (BGB-A317) for relapsed/refractory classical Hodgkin lymphoma: updated follow-up efficacy and safety results from a Phase 2 study
Abstract Code: PF469
Session Title: Hodgkin lymphoma – Clinical
Date: Friday, June 14
Time: 17:30 – 19:00 (CEST)
Lead Author: Yuqin Song, M.D., Ph.D.

Title: Major responses in MYD88 wildtype (MYD88WT) Waldenström Macroglobulinemia (WM) patients treated with Bruton Tyrosine Kinase (BTK) inhibitor zanubrutinib (BGB-3111)
Abstract Code: PF487
Session Title: Indolent and mantle-cell non-Hodgkin lymphoma – Clinical
Date: Friday, June 14
Time: 17:30 – 19:00 (CEST)
Lead Author: Meletios A. Dimopoulos, M.D.

Title: Updated safety and efficacy data in a Phase 1/2 trial of patients with Waldenström Macroglobulinaemia (WM) treated with the Bruton Tyrosine Kinase (BTK) inhibitor zanubrutinib (BGB-3111)
Abstract Code: PF481
Session Title: Indolent and mantle-cell non-Hodgkin lymphoma – Clinical
Date: Friday, June 14
Time: 17:30 – 19:00 (CEST)
Lead Author: Judith Trotman, MBChB, FRACP, FRCPA

Title: Pooled analysis of safety data from monotherapy studies of the Bruton Tyrosine Kinase (BTK) inhibitor, zanubrutinib (BGB-3111), in B-cell malignancies
Abstract Code: PS1159
Session Title: Chronic lymphocytic leukemia and related disorders – Clinical
Date: Saturday, June 15
Time: 17:30 – 19:00 (CEST)
Lead Author: Constantine S. Tam, M.D.
About BeiGene

BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team